Bank of America
ACHN

Bank of America’s Achillion Pharmaceuticals ACHN Stock Holding History

Bank of America’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-58,200
Closed -$267K – 7399
2017
Q2 		$267K Sell
58,200
-82,600
-59% -$332K ﹤0.01% 5192
2017
Q1 		$593K Buy
140,800
+98,800
+235% +$410K ﹤0.01% 4779
2016
Q4 		$173K Buy
+42,000
New +$223K ﹤0.01% 5388
2015
Q1 		– Sell
-74,000
Closed -$907K – 7776
2014
Q4 		$907K Buy
74,000
+31,400
+74% +$383K ﹤0.01% 4123
2014
Q3 		$425K Buy
42,600
+1,100
+3% +$10.2K ﹤0.01% 4742
2014
Q2 		$314K Buy
41,500
+36,600
+747% +$146K ﹤0.01% 5089
2014
Q1 		$16K Sell
4,900
-16,500
-77% -$57.7K ﹤0.01% 7020
2013
Q4 		$71K Sell
21,400
-400
-2% -$1.16K ﹤0.01% 6363
2013
Q3 		$66K Buy
+21,800
New +$149K ﹤0.01% 6255

Bank of America's ACHN Position: Q1 2020 in Review

Bank of America sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 197,794 shares — an estimated $1.19M sold.

Bank of America first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $8.47M in Q2 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

  • Bank of America reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Bank of America sold 197,794 Achillion Pharmaceuticals shares in Q1 2020, an estimated $1.19M.
  • Bank of America first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Bank of America's Achillion Pharmaceuticals position peaked at $8.47M in Q2 2015.
  • 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on Bank of America's 13F filing for Q1 2020, filed 15 May 2020.